Impact of fiducial markers placement on the delineation of target volumes in radiation therapy for oesophageal cancer: FIDUCOR study.
endoscopic ultrasound
fiducial markers (FMs)
oesophageal cancer
radiation therapy (radiotherapy)
target volumes
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
08
2022
accepted:
14
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
This prospective monocentric phase II study (FIDUCOR-study, NCT02526134) aimed to assess the impact of fiducial markers (FMs) implantation on conformal chemo-radiation therapy (CRT) planning in oesophageal carcinoma (EC) patients. Fifteen EC patients were enrolled in the study. Each patient underwent two simulation CT-scans before (CT1) and after (CT2) FMs implantation, in the same position. FMs (3 mm length gold markers, preloaded in a 22G needle) were implanted after sedation, under endoscopic ultrasound (EUS) and X-Ray guidance, and were placed at the tumor's extremities, and in the visible lymph nodes. Target delineation and treatment plan were both performed first on CT1 with the assistance of diagnosis CT, gastroscopy and EUS details, and second on CT2 using FMs and CT-data. The value of FMs implantation was assessed by the difference of growth-tumor-volume (GTV) and clinical-target-volume (CTV) between CT1-based and CT2-based delineation. A significant difference was defined as a ≥5 mm-difference on axial(x) or coronal(y) slices, a ≥10mm-difference on sagittal slices, or a ≥20%-difference in GTV. The impact on dose distribution in organs at risk (OAR) (lung, heart, liver) was also studied. Between 09/2014 and 12/2015, 15 patients could achieve fiducial procedures, without any complication. One FM migration occurred. We observed a significant modification of the GTV-dimension in 100% of the cases (15/15, 95%CI: [78.2;100.0]), mainly due to a difference in sagittal dimension with a mean variation of 11.2 mm and a difference> 10 mm for 8/15 patients (53.3%). One patient had a significant isocenter displacement as high as 20 mm. The oesophagus tumor was not seen on the CT-scan in one patient due to its small size. One patient had a distant lymph node metastasis not visible on CT-scan. We observed no significant impact on OAR distribution. In our study, FMs-implantation under EUS had a positive impact on accurate volume definition in EC-patients (modification of GTV in 15/15 patients). Close cooperation between gastroenterologist and radiation oncologist has the potential to improve local treatment of oesophageal carcinoma.
Identifiants
pubmed: 36387207
doi: 10.3389/fonc.2022.1012712
pmc: PMC9650130
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1012712Informations de copyright
Copyright © 2022 Rochigneux, Tyran, Autret, Lopez Almeida, Guiramand, Ferre, Chanez, Mitry, Ratone, Giovannini, Tallet, Moureau-Zabotto and Caillol.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Radiother. 2016 Sep;20 Suppl:S161-8
pubmed: 27523409
Ann Surg Oncol. 2003 Oct;10(8):954-60
pubmed: 14527917
Gastrointest Endosc. 2010 Mar;71(3):500-4
pubmed: 20189507
Radiology. 2003 Jun;227(3):764-70
pubmed: 12773680
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):911-20
pubmed: 26104943
Semin Nucl Med. 2007 May;37(3):206-22
pubmed: 17418153
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Gastrointest Endosc. 2010 Jun;71(7):1204-10
pubmed: 20598247
Med Phys. 2017 Dec;44(12):6570-6582
pubmed: 29023771
Radiother Oncol. 2006 Mar;78(3):254-61
pubmed: 16545881
Cancer Radiother. 2011 Oct;15(6-7):555-9
pubmed: 21802333
Strahlenther Onkol. 2010 Oct;186(10):544-50
pubmed: 20936461
Gastrointest Endosc. 2009 Sep;70(3):579-83
pubmed: 19560140
Gastrointest Endosc. 2010 Jun;71(7):1178-84
pubmed: 20362284
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):340-5
pubmed: 16168829
Gastrointest Endosc. 2010 Mar;71(3):630-3
pubmed: 20189527
Endosc Ultrasound. 2021 Mar-Apr;10(2):103-110
pubmed: 33666179
J Gastrointest Surg. 2004 Dec;8(8):988-96
pubmed: 15585386
Gastrointest Endosc. 2010 Mar;71(3):513-8
pubmed: 20189509
Gastrointest Endosc. 2011 Jun;73(6):1302-5
pubmed: 21481860
Endoscopy. 2010 May;42(5):423-5
pubmed: 20232282
Radiother Oncol. 2004 Dec;73(3):269-75
pubmed: 15588870
Br J Cancer. 1998 Aug;78(4):521-7
pubmed: 9716038
Gastrointest Endosc. 2006 Sep;64(3):412-7
pubmed: 16923491
Med Phys. 1995 Nov;22(11 Pt 2):1911-21
pubmed: 8587545
Gastrointest Endosc. 2015 Oct;82(4):641-9
pubmed: 25957478